Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share & Industry Analysis, By Drug Type (Chemotherapy Drugs, Targeted Drugs, Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Others)and Regional Forecast, 2024-2032

Lymphoma is cancer that affects the part of our immune system which is called a human lymphatic system. Lymphoma starts when the lymphocytes divide in an uncontrolled manner. B lymphocytes are responsible for large lymphomas. Thus, diffuse large B-cell generates from B cell large and abnormal and are a different form of a normal B cell. Globally, diffuse large B cell lymphoma (DLBCL) is considered to be a common type of non-hodgkin lymphoma (NHL) which is the fastest growing and affects B lymphocytes. These B cell lymphocytes help in fighting against infections and help in the proper functioning of the lymphatic system. Furthermore, DLBCL develops in extranodal sites which include thyroid, skin, gastrointestinal tract, bone, breast, and others. It is most commonly observed in men than in women. Moreover, this type of lymphoma has enlarged B cell and cancer cells that are in extend out the pattern. Symptoms of lymphoma are weight loss, rise in temperature without any cause, heavy sweating, and others which are boosting the growth of the market. Various tests are conducted for diagnosis of lymphomas such as blood tests, removal of lymph node, biopsy, and others that are positively influencing the market growth during the forecast period.

Technological advancement coupled with advanced drug therapeutics is upscaling the growth of the market. Moreover, the increase in the prevalence of diffuse large B-cell lymphoma, an increase in cancer patients, and others are driving some of the factors that are driving the market in the near future. According to, the Cancer Research U.K it is estimated that annually 5,500 people are diagnosed with DLBCL, which makes about 40% of NHL cases in adults. Moreover, pharmaceutical industries have shifted their focus towards the development of advanced therapeutics for the treatment of DLBCL. In addition to this, an increase in pipeline candidates for the development of drugs for faster recovery of DLBCL is also triggering the market growth during the forecast period. For instance, the launch of biosimilars of rituximab drug type which has obtained a huge market as monotherapy as well as combination therapy.

However, stringent regulations, delays in FDA approvals, patent expiry of drugs, and others are hindering the market growth during the forecast period. For instance, patent expiry of drugs like rituximab, which is widely used for the treatment of B-cell lymphoma, leading to the introduction of generics.

Key Players Covered:

Some of the major companies that are present in the global diffuse large B-cell lymphoma therapeutics market are Novartis AG, Pfizer Inc, Merck & Co., Inc., GlaxoSmithKline plc, Abbott, F. Hoffmann-La Roche Ltd., and other players.

Targeted drug type named Rituximab is anti-CD20 monoclonal antibody has gained huge market share. Owing to increase in demand for treatment of DLCBL and launch of biosimilars in the market.

Key Insights

• Prevalence of diffuse large B cell lymphoma (DLBCL)


• Overview of market share analysis


• Regulatory scenario for key countries


• New product launches


• Key industry developments

Regional Analysis:

The global diffuse large B cell lymphoma (DLBCL) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market followed by Europe due to a number of factors such as the increasing prevalence of chronic diseases, increasing prevalence of DLBCL cases, increased healthcare awareness, developed healthcare infrastructure, and others. The market in the Asia Pacific is anticipated to emerge as highly growing due to an increase in the geriatric population, improved R& D in countries in economically emerging countries such as China and India, and others. Latin America and Middle East & Africa are expected to experience steady growth.

Segmentation

Key Industry Developments

• In June 2019, FDA granted approval for product named Polatuzumab Vendotin-piiq (POLIVY) product of Genentech,Inc for the treatment of diffuse large B-cell lymopha